FDA approves Lynparza’s use in a wider group of women.
Circulating tumour cell test could help select drug therapy.
US biotech looks to bolster pipeline.
Tesara and Takeda among other companies to publish data.
Veliparib fails in two phase 3 trials.
Company nabs maintenance therapy use, but problems on breast cancer trial.
UK firm lays down the gauntlet in the PARP inhibitor battle.
UK pharma also gets $130m payment from Valeant.
Clovis’ Rubraca will compete against AstraZeneca rival.